clinical research organizations medical writing

“The quickest way to negatively impact timelines is to have quality issues that require rework,” said Regina Parott, Senior Manager, Medical Writing & Transparency, MMS. This was a key point brought back by Parott from a recent sponsor quality forum where it was indicated that additional drafts of key deliverables are a root cause of delayed timelines.

To avert this, “proper quality management should focus on how to prevent quality issues from occurring in the first place, not just managing them,” said Erin Booth Ph.D., Manager, Regulatory and Medical Writing.

Precision takes time, focus, and experience, but even the most experienced professionals can make mistakes. By implementing a few essential, learned behaviors, quality can increase immensely, according to Dr. Booth and Parott.

Getting it right the first time

“It is important to produce quality work from the start,” says Parott. “This comes from early engagement, a commitment to the value of good work, and being proactive.”

Parott is saying that it is not acceptable to send any document to a sponsor that is anything less than stellar. Often, folks may be tempted to believe this is just a first draft so it’s not that important. This is where issues begin. Additionally, clear six sigma and lean management concepts indicate that following the correct processes, proper training, and putting in the effort upfront will reduce quality issues and time spent later on rework.

“Even first drafts of a deliverable should be ‘near final’ upon delivery to a sponsor,” adds Parott.

Taking accountability for deliverables

“Being accountable for the work that is produced is a number one priority,” said Dr. Booth.

Sponsors expect clinical research organizations to hold themselves and the study teams accountable for following the correct process. If processes are not followed, quality can be negatively impacted and concerns may rise quickly.

Dr. Booth added “As experts, it is imperative to feel comfortable standing our ground when either quality or best practices are at risk.”

Working directly with other experts

Parott states, “Open communication is vital to our success.”

When a sponsor has separate writing and statistics vendors for example, issues in judgement between them may arise. In cases like this, vendors may want to work together to discover why specific decisions were made on both sides.

However, getting another vendor to admit they are wrong and make updates may be difficult. There is evidence that the human brain is programmed to make people think that they are correct, even is it’s abundantly clear that they are wrong.

“Sponsors shouldn’t have to be the go-between in situations like this,” said Parott. “It is much easier to bring a strong solution to the sponsor, allowing them to focus on other, more important items.”

Proactive quality risk management

Letting primary contacts know of quality concerns before they become reality may seem like common sense, but it is not that clear cut.

Dr. Booth suggests, “Have a plan and partner with sponsors in preventing risks to quality and timelines. Many times, people can be afraid to speak up in an effort not to halt progress. Stating potential issues or process deviations before they happen may save a considerable amount of budget in the future.”

It is clear that Dr. Booth and Parott believe that quality is every person’s job, no matter their job title. In this highly-educated industry, experts should feel comfortable in their knowledge and stand up for the correct course of action. And, if it is an oversight on the expert’s behalf they should be able to recognize and admit the mistake, and rectify the situation. These qualities are the composition of a true leader.

Suggested For You

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives

May 10th, 2024

Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives

April 29th, 2024

Validation of Clinical Dashboards for Decision Making